A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009652/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of
oral AP24534 in a defined schedule in patients with refractory or advanced chronic
myelogenous leukemia and other refractory hematologic malignancies.
提供机构：
Vivli
创建时间：
2023-12-21
